Literature DB >> 27355180

WNT5A and Its Receptors in the Bone-Cancer Dialogue.

Stefanie Thiele1, Tilman D Rachner1, Martina Rauner1, Lorenz C Hofbauer1,2,3.   

Abstract

Wnt signaling is critical for tumorigenesis and skeletal remodeling. However, its contribution to the formation of metastatic bone lesions remains poorly defined. One major challenge of unraveling its role in cancer progression is the high complexity of Wnt signaling, which includes numerous ligands, receptors, and inhibitors, with intricate biological effects and specific signaling pathways depending on the cellular context. In this perspective, we summarize the role of the noncanonical Wnt ligand WNT5A in the development and metastatic process of osteotropic cancer entities. We focus on its tumor-suppressive function in breast cancer, tumor promoting effects in melanoma, and ambiguous role in prostate cancer, and discuss potential challenges and opportunities that may be associated with targeting Wnt signaling for cancer therapy and treatment of bone metastases.
© 2016 American Society for Bone and Mineral Research. © 2016 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE; CANCER; WNT RECEPTORS; WNT5A

Mesh:

Substances:

Year:  2016        PMID: 27355180     DOI: 10.1002/jbmr.2899

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  9 in total

1.  Tumor suppressive functions of WNT5A in rhabdomyosarcoma.

Authors:  Nada Ragab; Julia Bauer; Anja Uhmann; Alexander Marx; Heidi Hahn; Katja Simon-Keller
Journal:  Int J Oncol       Date:  2022-07-07       Impact factor: 5.884

Review 2.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

3.  Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.

Authors:  Leah M Cook; Jeremy S Frieling; Niveditha Nerlakanti; Jeremy J McGuire; Paul A Stewart; Karen L Burger; John L Cleveland; Conor C Lynch
Journal:  Oncogene       Date:  2019-08-13       Impact factor: 9.867

4.  Molecular genetics and targeted therapy of WNT-related human diseases (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

5.  Identification of a novel cancer stem cell subpopulation that promotes progression of human fatal renal cell carcinoma by single-cell RNA-seq analysis.

Authors:  Xiu-Wu Pan; Hao Zhang; Da Xu; Jia-Xin Chen; Wen-Jin Chen; Si-Shun Gan; Fa-Jun Qu; Chuan-Min Chu; Jian-Wei Cao; Ying-Hui Fan; Xu Song; Jian-Qing Ye; Wang Zhou; Xin-Gang Cui
Journal:  Int J Biol Sci       Date:  2020-10-17       Impact factor: 6.580

6.  Wnt/β‑catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review).

Authors:  Gui-Xian Zhu; Dian Gao; Zhao-Zhao Shao; Li Chen; Wen-Jie Ding; Qiong-Fang Yu
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

7.  Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.

Authors:  Stefanie Thiele; Ariane Zimmer; Andy Göbel; Tilman D Rachner; Sandra Rother; Susanne Fuessel; Michael Froehner; Manfred P Wirth; Michael H Muders; Gustavo B Baretton; Franz Jakob; Martina Rauner; Lorenz C Hofbauer
Journal:  Oncotarget       Date:  2018-06-05

Review 8.  Emerging and Established Models of Bone Metastasis.

Authors:  Alexander H Jinnah; Benjamin C Zacks; Chukwuweike U Gwam; Bethany A Kerr
Journal:  Cancers (Basel)       Date:  2018-06-01       Impact factor: 6.639

9.  Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway.

Authors:  Ryan Green; Mark Howell; Roukiah Khalil; Rajesh Nair; Jiyu Yan; Elspeth Foran; Sandhyabanu Katiri; Jit Banerjee; Mandip Singh; Srinivas Bharadwaj; Shyam S Mohapatra; Subhra Mohapatra
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.